… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … 1/2 Stellar trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
… in 2021. “From previous clinical trials we have seen that RNA therapies can be a promising approach for patients with … are excited to have started a clinical trial for the third RNA therapy in our inherited retinal disease pipeline.” About …
… first studies of its kind exploring the impact of ProQR’s RNA therapies on patients with Usher syndrome due to an Exon … The STELLAR trial will explore whether QR-421a (ProQR’s RNA therapy) can slow disease progression or even reverse it. …
… to changing lives through the creation of transformative RNA therapies, today announced several presentations at the … About sepofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital … to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced its … “ProQR was founded with the goal of developing RNA therapies for patients with high unmet medical need, and … About Sepofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital …
… in 2019 as we advanced our portfolio of investigational RNA therapies for patients that suffer from inherited retinal … transplant. About QR-504a We are developing QR-504a as an RNA therapy for the treatment of FECD3. We plan to advance …